We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
-12.85%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.17B
AUM Growth
-$301M
(-21%)
Cap. Flow
-$33.3M
Cap. Flow
% of AUM
-2.85%
Top 10 Holdings %
Top 10 Hldgs %
56.5%
Holding
52
New
9
Increased
12
Reduced
9
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viatris
VTRS
|
+$83.6M |
| 2 |
MJN
Mead Johnson Nutrition Company
MJN
|
+$49.4M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
+$27.8M |
| 4 |
Tenet Healthcare
THC
|
+$25.8M |
| 5 |
HMSY
HMS Holdings Corp.
HMSY
|
+$24.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$48.6M |
| 2 |
MASI
Masimo
MASI
|
+$36.8M |
| 3 |
Dentsply Sirona
XRAY
|
+$25.8M |
| 4 |
Perrigo
PRGO
|
+$22.7M |
| 5 |
ESRX
Express Scripts Holding Company
ESRX
|
+$13.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 71.52% |
| 2 | Consumer Staples | 3.62% |
| 3 | Industrials | 1.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Abbott
ABT
$183B
| $12.1M | 1.03% |
+300,000
| New | +$14.1M |
|
|
DRRX
27
DELISTED
DURECT Corp
DRRX
| $11.7M | 1% |
600,000
+100,000
| +20% | +$2.27M |
|
28
Option Care Health
OPCH
$3.45B
| $11.2M | 0.96% |
1,500,000
+337,500
| +29% | +$3.41M |
|
29
OraSure Technologies
OSUR
$279M
| $8.88M | 0.76% |
2,000,000
+700,525
| +54% | +$3.66M |
|
30
Protalix BioTherapeutics
PLX
$191M
| $8.58M | 0.74% |
727,458
| – | – |
|
|
EPRS
31
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
| $8.17M | 0.7% |
1,847,500
| – | – |
|
|
ATXS
32
DELISTED
Astria Therapeutics
ATXS
| $8.09M | 0.69% |
16,667
+1,207
| +8% | +$862K |
|
|
NVTA
33
DELISTED
Invitae Corporation
NVTA
| $6.46M | 0.55% |
894,014
+394,014
| +79% | +$4.14M |
|
34
Insulet
PODD
$11.5B
| $6.35M | 0.54% |
+245,000
| New | +$7.43M |
|
|
GNMK
35
DELISTED
GenMark Diagnostics, Inc
GNMK
| $5.7M | 0.49% |
724,097
-293,800
| -29% | -$2.72M |
|
|
BIOL
36
DELISTED
Biolase, Inc.
BIOL
| $4.8M | 0.41% |
427
| – | – |
|
37
Veracyte
VCYT
$3.7B
| $4.27M | 0.37% |
910,334
-316,660
| -26% | -$3.02M |
|
38
AngioDynamics
ANGO
$611M
| $3.4M | 0.29% |
258,183
-477,200
| -65% | -$7.2M |
|
|
UNIS
39
DELISTED
Unilife Corporation
UNIS
| $2.69M | 0.23% |
+275,000
| New | +$4.1M |
|
|
CRDC
40
DELISTED
CARDICA INC COM NEW (DE)
CRDC
| $2.41M | 0.21% |
837,485
| – | – |
|
41
Gyre Therapeutics
GYRE
$641M
| $899K | 0.08% |
1,715
-266
| -13% | -$406K |
|
42
CALL
AstraZeneca
AZN
$263B
| $3K | ﹤0.01% |
+920,587
| New | +$60.6M |
|
|
43
Cigna
CI
$73.7B
| – | – |
-300,000
| Closed | -$48.6M |
|
44
CALL
Johnson & Johnson
JNJ
$618B
| – | – |
-500,000
| Closed | -$48.7M |
|
|
45
Perrigo
PRGO
$1.4B
| – | – |
-122,748
| Closed | -$22.7M |
|
46
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
| – | – |
-500,000
| Closed | -$103M |
|
47
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$41.9B
| – | – |
-1,000,000
| Closed | -$74.4M |
|
|
48
Dentsply Sirona
XRAY
$2.68B
| – | – |
-500,000
| Closed | -$25.8M |
|
|
BIOL
49
CALL
DELISTED
Biolase, Inc.
BIOL
| – | – |
-147
| Closed | -$82K |
|
|
KERX
50
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| – | – |
-500,000
| Closed | -$4.99M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q3 2015 Portfolio in Review
As of Q3 2015, Camber Capital Management held 52 positions worth $1.17B, down 21% from $1.47B the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Camber Capital Management's Q3 2015 filing shows 9 new, 12 increased, 9 reduced and 8 closed positions. Its largest new stake was Viatris: 1,500,000 shares worth $60.4M. The largest sale was Cigna, an estimated $48.6M.
By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 66% a quarter earlier, followed by Consumer Staples and Industrials.
- Camber Capital Management's largest Q3 2015 buy was Viatris: 1,500,000 shares worth $60.4M.
- Camber Capital Management added most to Teva Pharmaceuticals in Q3 2015, an estimated $16.2M increase.
- Camber Capital Management's biggest Q3 2015 reduction was Masimo, cutting an estimated $36.8M.
- Camber Capital Management fully exited Cigna in Q3 2015, selling an estimated $48.6M.
- Camber Capital Management's ten largest holdings make up 57% of its $1.17B portfolio in Q3 2015.
- Camber Capital Management opened 9 new positions and closed 8 in Q3 2015.
- Camber Capital Management's portfolio value fell 21% quarter-over-quarter to $1.17B.
Based on Camber Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.